November 2013 Safety Labeling Changes includes 27 products with revisions to prescribing information

The MedWatch November 2013 Safety Labeling Changes posting includes 27 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The "Summary Page" provides a listing of product names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm377096.htm

The following drugs had modifications to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:

Prevpac (Lansoprazole 30 mg delayed-release, Amoxicillin 500 mg capsules and Clarithromycin 500 mg tablets)
Zestoretic (Lisinopril/Hydrochlorothiazide)
Zestril (Lisinopril)
Amturnide (Aliskiren, Amlodipine and Hydrochlorothiazide)
Aralen (Chloroquine Phosphate) 
Jakafi (Ruxolitibib)
Lysodren (Mitotane)
Nexavar (Sorafenib)
Noxafil (Posaconazole)   
Onfi (Clobazam)     
Remicade (Infliximab)
Revlimid (Lenalidomide)
Simponi (Golimumab)
Tekamlo (Aliskiren and Amlodipine)
Tekturna (Aliskiren)
Tekturna HCT (Aliskiren and Hydrochlorothiazide)
Xalkori (Crizotinib)

Recyclable pill bottles are gaining pharmacy ground
Aluminum and paper-based prescription bottles are moving from concept to commercial reality. Here's what pharmacy and packaging leaders need to know.
Read More
Recyclable pill bottles are gaining pharmacy ground
Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026